AB Science SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
AB Science SA Announces that European Medicines Agency Accepts Marketing Application for Masitinib in the Treatment of Gleevec resistant Gastro-Intestinal Stromal Tumor
AB Science SA announced that the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for masitinib in the treatment of patients with Gleevec-resistant gastro-intestinal stromal tumors (GIST). Filing for the Marketing Authorization of masitinib in GIST resistant to Gleevec was accepted by EMA on the basis of results from a phase II study that showed masitinib to improve overall survival in patients with Gleevec-resistant GIST as compared with Sutent (sunitinib) from Pfizer, which is currently the standard of care for second-line treatment of GIST.
Latest Developments for AB Science SA
- AB Science SA and Skuldtech Announce the Identification of New Predictive Markers for Pancreatic Cancer Survival Associated with Masitinib Treatment
- AB Science SA Announces Publication of Results from the Human Phase 2 Study of Masitinib
- AB Science SA Reports Positive Clinical Study Data: Masitinib Significantly Extends Overall Survival in Patients with Gleevec-resistant Gastrointestinal Stromal Tumors
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this